Susquehanna Fundamental Investments LLC Has $1.81 Million Stock Holdings in AnaptysBio, Inc. (NASDAQ:ANAB)

Susquehanna Fundamental Investments LLC grew its holdings in AnaptysBio, Inc. (NASDAQ:ANAB) by 32.9% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 72,060 shares of the biotechnology company’s stock after acquiring an additional 17,855 shares during the quarter. Susquehanna Fundamental Investments LLC’s holdings in AnaptysBio were worth $1,806,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. First Light Asset Management LLC lifted its holdings in shares of AnaptysBio by 56.4% during the 4th quarter. First Light Asset Management LLC now owns 1,237,178 shares of the biotechnology company’s stock worth $26,500,000 after acquiring an additional 446,372 shares during the period. StemPoint Capital LP lifted its stake in shares of AnaptysBio by 499.0% in the 1st quarter. StemPoint Capital LP now owns 269,548 shares of the biotechnology company’s stock valued at $6,070,000 after acquiring an additional 224,548 shares during the last quarter. Octagon Capital Advisors LP bought a new stake in AnaptysBio during the 4th quarter worth $2,570,000. Assenagon Asset Management S.A. raised its position in AnaptysBio by 38.2% in the second quarter. Assenagon Asset Management S.A. now owns 306,633 shares of the biotechnology company’s stock valued at $7,684,000 after purchasing an additional 84,795 shares during the last quarter. Finally, Great Point Partners LLC boosted its stake in shares of AnaptysBio by 9.2% during the fourth quarter. Great Point Partners LLC now owns 976,981 shares of the biotechnology company’s stock valued at $20,927,000 after purchasing an additional 82,648 shares in the last quarter.

AnaptysBio Price Performance

NASDAQ ANAB opened at $34.81 on Wednesday. The company has a fifty day moving average price of $35.64 and a 200-day moving average price of $28.25. AnaptysBio, Inc. has a 1 year low of $13.36 and a 1 year high of $41.31. The firm has a market cap of $950.97 million, a price-to-earnings ratio of -5.67 and a beta of -0.29.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($1.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.82). The company had revenue of $10.97 million for the quarter, compared to analysts’ expectations of $25.85 million. AnaptysBio had a negative return on equity of 255.68% and a negative net margin of 558.25%. On average, research analysts anticipate that AnaptysBio, Inc. will post -6.84 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently issued reports on ANAB. JPMorgan Chase & Co. raised their price objective on shares of AnaptysBio from $69.00 to $75.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. Wedbush reiterated an “outperform” rating and set a $42.00 price target on shares of AnaptysBio in a report on Thursday, September 26th. HC Wainwright restated a “buy” rating and issued a $55.00 price objective on shares of AnaptysBio in a report on Wednesday, August 14th. Finally, Truist Financial lifted their price objective on AnaptysBio from $20.00 to $30.00 and gave the stock a “hold” rating in a research note on Thursday, August 15th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $51.10.

Insider Activity at AnaptysBio

In other news, major shareholder Ecor1 Capital, Llc bought 273,972 shares of the firm’s stock in a transaction on Wednesday, August 14th. The stock was acquired at an average cost of $36.50 per share, with a total value of $9,999,978.00. Following the completion of the transaction, the insider now directly owns 7,794,996 shares of the company’s stock, valued at approximately $284,517,354. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other AnaptysBio news, Director Hollings Renton sold 10,000 shares of AnaptysBio stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $30.64, for a total transaction of $306,400.00. Following the completion of the transaction, the director now owns 1,950 shares of the company’s stock, valued at approximately $59,748. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Ecor1 Capital, Llc bought 273,972 shares of the stock in a transaction on Wednesday, August 14th. The stock was purchased at an average price of $36.50 per share, for a total transaction of $9,999,978.00. Following the completion of the purchase, the insider now directly owns 7,794,996 shares in the company, valued at $284,517,354. The disclosure for this purchase can be found here. Over the last quarter, insiders have sold 33,940 shares of company stock worth $1,251,836. Insiders own 33.70% of the company’s stock.

AnaptysBio Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.